Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation

Overview of attention for article published in Pharmacogenomics and Personalized Medicine, March 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#35 of 372)
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

卵巢癌PARPi维持治疗耐药因BRCA1致病性体系突变消失？

CN-Healthcare, 04 Sep 2023

本文报告了1例初诊为晚期HGSOC患者，携带致病性BRCA1体系突变，经一线肿瘤细胞减灭术和铂类化疗后，接受PARPi奥拉帕利治疗，发生耐药。伴有胚系和致病性体系BRCA1/2突变的晚期上皮性卵巢癌（EOC）患者，PARP抑制剂（PARPi）是一线铂类化疗…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.